AI tools like PathomIQ can predict prostate cancer metastasis by analyzing whole-slide images, independent of Gleason scores and gene expression profiling. Current AI applications in prostate cancer ...

A primary concern was establishing trust in the connectivity to ensure no loss in visualization or connection. Urologists from Cleveland Clinic recently collaborated across borders to perform the ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD. “We're now entering an era of new types of technologies to treat BPH in a ...

“What [we] found was that those men who received a penile implant had a significant reduction in depression and psychological distress," says Mohit Khera, MD, MBA, MPH. Implantable penile prosthesis ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition. At this year ...

Clarius Prostate AI reduces prostate volume measurement time from minutes to seconds, enhancing clinical efficiency. The application integrates with Clarius handheld ultrasound scanners and calculates ...

Experts discuss their expectations regarding the uptake of new treatments in clinical practice for non–muscle-invasive bladder cancer and other relevant conditions. Stay current with the latest ...

"We found that female patients, Black patients, and patients with non-private insurance had a decreased odds of receiving opioids,” says Hailey Frye. Researchers from the University of Minnesota, ...

The proposed budget cut reduces CDMRP funding from $1.509 billion in FY2024 to $650 million in FY2025, affecting cancer research funding. Organizations like Zero Prostate Cancer and the American ...

The updated guideline includes 25 recommendations, emphasizing risk stratification and minimizing unnecessary evaluations for low-risk patients. New guidance incorporates urine-based tumor markers for ...